Thanks Doc. I’m pretty sure the small dilution was warrants being exercised since LPC tapping is not allowed under $3 per share and Anavex stated clearly that none of the Cantor ATM has been utilized yet.
One take is it could mean confidence in PDD success by management.
I’m with you on expected increases in clinical trial costs in the near future.
PDD seems to definitely be the point of emphasis lately. Could that be because they think it’s the best indication to allow for the lower doses to be effective? I just cannot shake the feeling that something is wonky about the refusal to register the Alzheimer’s trial and specify the titration regime for Rett and only administer 10 and 20 mgs for PDD. It seems “odd” imho , it’s almost like they are “hiding” anything that is related to the 30 and 50 mg doses.
To me this also seems “weird”.
“The most common side effects across all AE categories tended to be of mild severity grade 1 and were resolved with dose reductions that were anticipated within the adaptive design of the study protocol.”
Aren’t grade 1 ae’s allowed all the time in clinical trials? Why did they make that part of their trial design?
The foot dragging on the Az trial could be related to the 40% rebate timing imho to slow cash burn.
News 
Market Data 
Discover 
